Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma 43Breast Neoplasms 37Lymphoma, Large B-Cell, Diffuse 29Sarcoma 20Lymphoma, Non-Hodgkin 17Burkitt Lymphoma 16Neuroblastoma 15Leukemia 13HIV Infections 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Hodgkin Disease 11Acquired Immunodeficiency Syndrome 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Ovarian Neoplasms 9Multiple Myeloma 9Carcinoma, Hepatocellular 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Liver Neoplasms 8Liposarcoma 7Breast Neoplasms, Male 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Anaplastic 6Fallopian Tube Neoplasms 6Sarcoma, Kaposi 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell 5Lung Neoplasms 5Histiocytoma, Malignant Fibrous 5Fibrosarcoma 5

Interventions

Temozolomide 3Vincristine 2Irinotecan 2Cyclophosphamide 2veliparib 1gallium Ga 68 dotatate 1entinostat 1carboxyamido-triazole 1adavosertib 1Verteporfin 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Paclitaxel 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Immunoglobulin G 1Filgrastim 1Etoposide 1Erlotinib Hydrochloride 1Doxorubicin 1Disulfides 1Congresses as Topic 1Cisplatin 1Chemotherapy, Adjuvant 1Carmustine 1Bevacizumab 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroectodermal Tumors, Primitive × Doxorubicin × Clear all
NCT00001209 2008-03-04

A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
120 enrolled
Sarcoma

Sarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡